SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CF Acquisition Corp. VI operates as a blank check company. It focuses on the search of companies in the financial services, healthcare, real estate services, technology and software industries. The company was founded on April 17, 2020 and is headquartered in New York, NY.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending after announcing a massive $13.7 billion six-year GPU cloud services agreement for its Maysville facility, with community members focused on how the deal validates the company's AI infrastructure thesis despite potential dilution and financing requirements. Investors are actively debating the impact of the contract's warrant structure and the potential for a short squeeze given the high short interest and the scale of the long-term revenue opportunity.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the community debates whether the asset will break through the $80,000 level or face a potential rejection and pullback. Investors are closely monitoring treasury bond yields and potential government actions, with many traders discussing the prospects of a sustained rally toward new all-time highs.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await clarity on the FDA's regulatory path for deramiocel, with many focused on the potential for a PDUFA extension following the company's submission of a major BLA amendment. Community sentiment remains highly polarized, pitting retail bulls anticipating a significant squeeze against shorts and skeptics concerned about long-term financial viability and regulatory hurdles.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors monitor reports that its REGAL Phase 3 trial may have reached the 80th event, a key catalyst for final analysis. While the community is actively debating the credibility of this unconfirmed milestone and potential buyout interest, sentiment remains divided between hopeful bulls and skeptics questioning the trial's official status.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba shares are trending as investors weigh the potential of the company's aggressive AI-focused equity raise against broader concerns about immediate dilution and the impact of elevated infrastructure spending. The community remains divided, with some retail traders holding a bullish outlook on long-term AI integration while others express frustration over the timing of the share sale and historical price performance.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is seeing increased retail interest following the reveal of its humanoid robot production goals and the upcoming launch of the MONA L03 model, as investors debate whether the company should be valued primarily as an EV manufacturer or an emerging leader in physical AI. While some remain wary of broader market pressure on Chinese equities, many are highlighting the firm's technological stack and software partnerships as potential long-term catalysts.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as investors react to the company's newly established $1.59 billion USD cash pool and its ongoing accumulation strategy, with bullish community sentiment driven by Bitcoin's push toward $80,000. Traders are actively debating the stock's performance relative to Bitcoin, focusing on the potential for a short squeeze as the asset price holds momentum.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is trending as investors monitor its aggressive accumulation of Ethereum and treasury buyback strategy, with the community closely tracking whether the company will complete its ownership target and cease share dilution. Discussion remains highly polarized, as bulls anticipate a parabolic move driven by crypto liquidity, while some investors express frustration over the stock's sensitivity to crypto conditions and historical performance relative to direct Ethereum holdings.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

PDD is trending as investors weigh strong profitability and advertising revenue growth against slowing top-line expansion and persistent regulatory and geopolitical headwinds. The community remains deeply divided, with many focusing on the company's robust cash balance and valuation, while others remain wary of long-term risks surrounding Chinese ADRs.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing intense scrutiny after the FDA issued a clinical hold on its RGX-121 gene therapy due to asymptomatic spinal MRI findings, causing shares to plunge. While the company stated it will not resubmit its marketing application in the near term, investors are debating whether the market overreacted, with many pointing to the benign nature of the findings and the ongoing progress of their Duchenne and retinal disease pipelines.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NIU I bought in around $5 and averaged down buying the dips. After about 3 years of going nowhere I&#39;m not buying anymore. My money can alot more elsewhere. No dividends,  no capital growth, only 3 years of hope that it will rise significantly,  which it hasn&#39;t. Why buy any more

Scott

StockTwits Web

Niu Technologies

 I bought in around $5 and averaged down buying the dips. After about 3 years of going nowhere I'm not buying anymore. My money can alot more elsewhere. No dividends,  no capital growth, only 3 years of hope that it will rise significantly,  which it hasn't. Why buy any more